JP2008518999A5 - - Google Patents

Download PDF

Info

Publication number
JP2008518999A5
JP2008518999A5 JP2007539549A JP2007539549A JP2008518999A5 JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5 JP 2007539549 A JP2007539549 A JP 2007539549A JP 2007539549 A JP2007539549 A JP 2007539549A JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
phenyl
optionally substituted
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007539549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518999A (ja
Filing date
Publication date
Priority claimed from EP04026441A external-priority patent/EP1655283A1/en
Application filed filed Critical
Publication of JP2008518999A publication Critical patent/JP2008518999A/ja
Publication of JP2008518999A5 publication Critical patent/JP2008518999A5/ja
Abandoned legal-status Critical Current

Links

JP2007539549A 2004-11-08 2005-11-08 11β−HSD1阻害剤 Abandoned JP2008518999A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04026441A EP1655283A1 (en) 2004-11-08 2004-11-08 11beta-HSD1 Inhibitors
PCT/EP2005/011933 WO2006048330A1 (en) 2004-11-08 2005-11-08 11βετα-hsd1 inhibitors

Publications (2)

Publication Number Publication Date
JP2008518999A JP2008518999A (ja) 2008-06-05
JP2008518999A5 true JP2008518999A5 (cg-RX-API-DMAC7.html) 2008-12-25

Family

ID=34927280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539549A Abandoned JP2008518999A (ja) 2004-11-08 2005-11-08 11β−HSD1阻害剤

Country Status (7)

Country Link
US (1) US20090069323A1 (cg-RX-API-DMAC7.html)
EP (2) EP1655283A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008518999A (cg-RX-API-DMAC7.html)
AT (1) ATE427932T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005013812D1 (cg-RX-API-DMAC7.html)
DK (1) DK1814846T3 (cg-RX-API-DMAC7.html)
WO (1) WO2006048330A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
KR101496190B1 (ko) 2005-01-05 2015-02-26 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CA2594116A1 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007138112A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
EP2139852A1 (en) 2006-12-19 2010-01-06 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
BRPI0921299A2 (pt) 2008-11-21 2015-08-25 High Point Pharmaceuticals Llc Compostos de benzamida adamantila
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
CN101838227A (zh) * 2010-04-30 2010-09-22 孙德群 一种苯甲酰胺类除草剂的安全剂
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
BR112013008898A2 (pt) * 2010-10-11 2016-06-28 Auckland Uniservices Limited benzamidas substituídas e seus usos
CA2826648C (en) 2011-02-18 2019-06-04 Endo Pharmaceuticals Inc. Aminoindane compounds and use thereof in treating pain
CN103732589B (zh) 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
MX2014008604A (es) 2012-01-31 2014-08-22 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2.
AR089771A1 (es) * 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
WO2014028675A1 (en) 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
CA2886831A1 (en) 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
HRP20191327T1 (hr) 2015-06-03 2019-11-01 Bristol Myers Squibb Co 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
EP3571193B1 (en) 2017-01-23 2021-12-01 Cadent Therapeutics, Inc. Potassium channel modulators
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206219D0 (en) * 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
JP2006514102A (ja) * 2002-11-07 2006-04-27 アストラゼネカ アクチボラグ 2−オキソ−エタンスルホンアミド誘導体

Similar Documents

Publication Publication Date Title
Lamberth et al. Bioactive carboxylic compound classes: pharmaceuticals and agrochemicals
CA2502269A1 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2018253864B2 (en) Ferroportin-inhibitor salts
JP2006510630A5 (cg-RX-API-DMAC7.html)
Emmitte mGlu5 negative allosteric modulators: a patent review (2010–2012)
Karabanovich et al. Development of 3, 5-dinitrobenzylsulfanyl-1, 3, 4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating Mycobacterium tuberculosis
DK2291080T3 (en) Novel modulator of sphingosinphosphatreceptorer
Phillips et al. Discovery of trifluoromethyl (pyrimidin-2-yl) azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure–activity relationships, lead optimization, and chronic in vivo efficacy
CA2646962A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
CA2593264A1 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
ME02323B (me) Spiro supstituisana jedinjenja kao inhibitori angiogeneze
JP2007507551A5 (cg-RX-API-DMAC7.html)
CA2522435A1 (en) Inhibitors of akt activity
JP2010523653A5 (cg-RX-API-DMAC7.html)
IL287159B1 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
RU2006134004A (ru) Производные гетероариламинопиразола, пригодные для лечения диабета
RU2010127297A (ru) 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний
Craig et al. Discovery of DNL343: a potent, selective, and brain-penetrant eIF2B activator designed for the treatment of neurodegenerative diseases
TW200920361A (en) Compounds useful as medicaments
KR20190020170A (ko) 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법
WO2009017098A1 (ja) トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体
JP2017508795A5 (cg-RX-API-DMAC7.html)
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5